
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1010 | 1010 | 1009 | 1011 | 1457 | 2288 |
Fund Return | 1% | 1% | 0.86% | 0.38% | 7.82% | 8.63% |
Place in category | 231 | 231 | 60 | 123 | 61 | 2 |
% in Category | 34 | 34 | 10 | 20 | 14 | 1 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Adamant Medtech B CHF | 1.37B | 0.83 | -0.32 | 7.86 | ||
Adamant Medtech T CHF | 1.37B | 0.93 | 0.08 | 8.29 | ||
Baloise Fund Invest Lux BFI C QUADr | 127.05M | -3.51 | -0.77 | -0.47 | ||
Entrepreneur Europe small B CHF | 116.83M | 7.02 | 0.80 | 4.99 | ||
Entrepreneur Europe small I CHF | 116.83M | 7.21 | 1.51 | 5.75 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Adamant Medtech B CHF | 1.37B | 0.83 | -0.32 | 7.86 | ||
Adamant Medtech T CHF | 1.37B | 0.93 | 0.08 | 8.29 | ||
BB Adamant Global Healthcare Index | 152.02M | -1.04 | -4.40 | 4.77 | ||
BB Adamant Global Medtech und Serv | 67.17M | 4.36 | -2.10 | 7.59 | ||
BB Adamant Global Medtech und Servi | 67.17M | 4.52 | -1.51 | 8.21 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Abbott Labs | US0028241000 | 10.16 | 128.29 | +1.11% | |
Boston Scientific | US1011371077 | 10.00 | 94.48 | +0.86% | |
Stryker | US8636671013 | 9.83 | 352.23 | +0.56% | |
Intuitive Surgical | US46120E6023 | 9.37 | 497.95 | +0.88% | |
EssilorLuxottica | FR0000121667 | 5.09 | 248.80 | +3.15% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review